FDA revises draft guidance on rare disease drug R&D
The FDA has updated a 2015 draft guidance on rare diseases, with new information gleaned since the original draft was released.
Among the revisions to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
